MedPath

Cell>Point LLC

Cell>Point LLC logo
🇺🇸United States
Ownership
Holding
Established
2001-01-01
Employees
11
Market Cap
-
Website
http://cellpointweb.com

Clinical Trials

5

Active:0
Completed:3

Trial Phases

3 Phases

Phase 1:1
Phase 2:3
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (60.0%)
Phase 1
1 (20.0%)
Phase 3
1 (20.0%)

Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)

Phase 2
Not yet recruiting
Conditions
Coronary Artery Disease
First Posted Date
2013-07-16
Last Posted Date
2025-04-01
Lead Sponsor
Cell>Point LLC
Target Recruit Count
60
Registration Number
NCT01899833
Locations
🇺🇸

Tom Hennebry, MD, Oklahoma City, Oklahoma, United States

A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD)

Phase 2
Completed
Conditions
Coronary Artery Disease
First Posted Date
2013-01-29
Last Posted Date
2013-07-12
Lead Sponsor
Cell>Point LLC
Target Recruit Count
2
Registration Number
NCT01778218
Locations
🇺🇸

Cardiovascular Imaging Technologies, Kansas City, Kansas, United States

A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer

Phase 3
Not yet recruiting
Conditions
Lung Cancer
Interventions
Drug: 18 F FDG followed by PET/CT imaging
Drug: (99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)
First Posted Date
2011-07-14
Last Posted Date
2025-04-03
Lead Sponsor
Cell>Point LLC
Target Recruit Count
154
Registration Number
NCT01394679
Locations
🇺🇸

Decatur Memorial Hospital, Decatur, Illinois, United States

Phase 2 Study Comparing 99mTc-EC-DG SPECT/CT With 18F FDG PET/CT in Patients With Non-small Cell Lung Cancer (NSCLC)

Phase 2
Completed
Conditions
Non Small Cell Lung Cancer
First Posted Date
2009-03-19
Last Posted Date
2013-03-22
Lead Sponsor
Cell>Point LLC
Target Recruit Count
22
Registration Number
NCT00865319
Locations
🇺🇸

Baptist Health South Florida, Coral Gables, Florida, United States

🇺🇸

Decatur Memorial Hospital Department of Radiology, Decatur, Illinois, United States

🇺🇸

John Hopkins University, Baltimore, Maryland, United States

and more 3 locations

Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)

Phase 1
Completed
Conditions
Non Small Cell Lung Cancer
First Posted Date
2009-03-18
Last Posted Date
2013-03-22
Lead Sponsor
Cell>Point LLC
Target Recruit Count
4
Registration Number
NCT00864110
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

Mayo Clinic, Division of Nuclear Medicine, Rochester, Minnesota, United States

🇺🇸

Montefiore Medical Center, Bronx, New York, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath